4See Ventures

PowerAPI provides businesses, including corporates, service and product integrators, agencies, and the public sector, with white label plug-and-play tools designed to facilitate digitalization and enhance product offerings. The platform offers an all-in-one operational software solution that helps small and medium-sized businesses manage their entire technology stack, automate operations, and simplify administrative tasks. By utilizing PowerAPI's OpenAPI and SDKs, clients can achieve seamless integration and benefit from dedicated support through a partner success team. This comprehensive approach enables organizations to grow their online revenues and accelerate new business opportunities while ensuring a quick go-to-market strategy.

HAYA Therapeutics is focused on developing RNA-based therapeutics aimed at treating heart failure and other fibrotic diseases. The company's innovative approach involves targeting a heart-specific regulator of fibrosis, specifically a long noncoding RNA, to block myocardial fibrosis. This biopharmaceutical therapy aims to improve the efficacy and safety of treatment for heart-related illnesses and other serious health conditions associated with aging, including cancer. By concentrating on tissue and cell-selective genomic medicines, HAYA Therapeutics seeks to provide more precise and effective therapeutic options for patients suffering from these conditions.

CYSEC is a startup focused on advancing Confidential Computing solutions that protect data throughout its lifecycle—at rest, in motion, and in use. The company has developed a cloud-based data security software that operates through a physical enterprise-grade server appliance, ensuring the integrity and confidentiality of data stored in the cloud. Their flagship product, the ARCA solution, is gaining popularity in the market for its effectiveness in safeguarding assets. By enabling businesses to innovate in the realm of confidential computing, CYSEC aims to provide robust cybersecurity systems applicable across various sectors.

HAYA Therapeutics is focused on developing RNA-based therapeutics aimed at treating heart failure and other fibrotic diseases. The company's innovative approach involves targeting a heart-specific regulator of fibrosis, specifically a long noncoding RNA, to block myocardial fibrosis. This biopharmaceutical therapy aims to improve the efficacy and safety of treatment for heart-related illnesses and other serious health conditions associated with aging, including cancer. By concentrating on tissue and cell-selective genomic medicines, HAYA Therapeutics seeks to provide more precise and effective therapeutic options for patients suffering from these conditions.

HAYA Therapeutics is focused on developing RNA-based therapeutics aimed at treating heart failure and other fibrotic diseases. The company's innovative approach involves targeting a heart-specific regulator of fibrosis, specifically a long noncoding RNA, to block myocardial fibrosis. This biopharmaceutical therapy aims to improve the efficacy and safety of treatment for heart-related illnesses and other serious health conditions associated with aging, including cancer. By concentrating on tissue and cell-selective genomic medicines, HAYA Therapeutics seeks to provide more precise and effective therapeutic options for patients suffering from these conditions.

keepMED Ltd. is a company focused on developing and commercializing innovative solutions for the treatment of Obstructive Sleep Apnea (OSA), a condition marked by repeated episodes of upper airway obstruction during sleep. The company's primary product, keePAP, is a lightweight and unobtrusive wearable device that includes a nasal interface and a miniature battery-operated control unit. Founded in 2012 and based in Rishon Le Zion, Israel, keepMED aims to provide effective treatment options for individuals suffering from OSA.